• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Bye-Bye China?

    Decentralized Trials Fuel AI Revolution in Clinical Research

    Self-Medication: Flexibility for Patients and Drug Manufacturers

    The Single-Use Mixing Landscape: Evaluating Your Options

    DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    KORSCH, MEDELPHARM Partner on R&D Equipment Portfolio

    Frontage Bolsters Clinical Services Capabilities

    Sanofi Unveils EUROAPI as Name of New European API Company

    Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz

    Precision Medicine Group Acquires Project Farma
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Sanofi Unveils EUROAPI as Name of New European API Company

    Precision Medicine Group Acquires Project Farma

    Cytiva Delivers Modular Biologics Factory to Lonza

    Fujifilm, CABIM Get $76M Funding for Mfg. and Innovation Center

    LSNE Expands Fill Finish and Lyophilization Ops
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Catalent Acquires Acorda’s INBRIJA Manufacturing Operations

    Varcode, PL Developments Form Strategic ‘Smart Tag’ Pact

    COVID-19 Vaccine Distribution: The Air Cargo Industry’s Greatest Challenge

    Thermo Fisher Expands Clinical Supply Services in Europe

    Schreiner MediPharm Joins DoseID Consortium
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Virtual Clinical Trials: The Future of Dermatology Studies

    Frontage Bolsters Clinical Services Capabilities

    Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz

    Precision Medicine Group Acquires Project Farma

    Cytiva Delivers Modular Biologics Factory to Lonza
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management

    CDMO Cognate BioServices Teams Up with L7 Informatics

    The Wasdell Group Earns ISO 13485 Certification
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Flow Sciences

    Reed-Lane

    Cytovance Biologics

    Aphena Pharma Solutions

    Emergent BioSolutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    PCI Pharma Services

    Baxter BioPharma Solutions

    Syngene

    Aphena Pharma Solutions

    Adare Pharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    FDA Watch

    Warning Letters & Close-out Letters

    Why does it take so long to get a close-out letter?

    Related CONTENT
    • Mogene
    • Know the Challenges of Biosimilar Manufacturing
    • Will Immunotherapy Knock Out Cancer?
    • Tapemark Passes Regulatory Hurdle
    • BioPharma Services Completes 3 FDA Inspections
    06.06.17
    One of the enforcement tools that FDA has in its toolbox is the Warning Letter. Most people in the pharmaceutical industry are quite familiar with Warning Letters. For all Warning Letters issued on or after September 1, 2009, FDA will issue a close-out letter for Warning Letters when all observations have been appropriately resolved, which basically states that the FDA is satisfied with a company’s response, corrective actions, and subsequent actions. This was intended to give industry clarity about the status of their sites, and to provide consumers, buyers, and potential partners insight into the state of compliance of manufacturers. In theory, it is possible to aggressively manage remediation and to satisfy FDA to get the Warning Letter lifted in an expeditious manner; however, a quick review of available data shows that this isn’t always the case.

    I’ve reviewed Warning Letters and close-out letters for the last several years, and find that the length of time to achieve close-out can be two plus years. For example, in 2014, there were 16 Warning Letters issued for drug facilities, but only 11 have subsequently received close-out letters. For Warning Letters issued in 2014, which have been closed-out, the average time for API facilities from issuance of a Warning Letter to close-out was 795 days, and the average time for finished dosage form facilities was 555 days. Add to those numbers the fact that there are 5 Warning Letters from 2014 that still haven’t been closed-out. If these Warning Letters are lifted, those statistics will climb. Similarly, in 2015 there were 20 Warning Letters issued, with only 3 closed-out to date. In 2016, there were 44 Warning Letters issued, with only 3 closed-out to date. Average time to closure with respect to Warning Letters issued in both 2015 and 2016 is currently much lower than those issued in 2014, but there is also a much lower percentage of close-outs relative to the total amount of Warning Letters issued, so average close-out time for Warning Letters issued in 2015 and 2016 is likely to rise if and when more close-outs occur.

    The time from receipt of a 483 to issuance of a Warning Letter has also risen over the last several years, with many Warning Letters being issued over a year after the 483 was issued. This adds to the overall time that companies are in limbo, without a clear direction as to their compliance status in the eyes of FDA.

    What are some of the possible reasons that it is taking so long for companies to resolve Warning Letters to FDA’s satisfaction? We believe it is attributable to any one (or a combination) of the following factors:

    Inadequate initial response to the Warning Letter
    When FDA issues a Warning Letter, generally it is because they have some concerns over the firm’s response to one or more 483s. However, at times, companies make the mistake of just reiterating the responses they gave in the initial 483 response when responding to a Warning Letter. Just restating the same thing isn’t going to change FDA’s mind. It’s very unlikely that FDA missed something in your initial response that would change its mind. Companies need to break down the Warning Letter citations to determine where they went wrong with the initial response, and try to rectify it.

    Another issue that makes companies’ responses inadequate in FDA’s eyes is when they are very narrow. If the FDA cited something in one system, or for one product, the firm needs to assess similar situations for other products or systems. Good responses look at overall systems, across the entire product line, site, and even across sites. This lets FDA know that you are serious about examining your entire systems and operations.

    Another pitfall that companies make is not implementing interim controls. If you have determined that an effective corrective action is going to take a year to implement, and you haven’t implemented an interim control in that year, you are still manufacturing product under the same objectionable conditions that FDA observed and cited, and that will erode FDA’s confidence in your company. Closely related to this failure is not assessing the impact of the Warning Letter citations on product currently on the market. Remember that FDA’s mission is to protect public health, and a response that doesn’t take this into consideration will be seen by FDA as inadequate.

    Not providing periodic updates
    Unless everything that you have committed to do has been completed prior to sending in your Warning Letter response, it’s important to keep FDA updated regularly. We’ve seen examples of companies that have committed to periodic updates and haven’t submitted them, haven’t had any dialogue with FDA, and then are surprised when FDA hasn’t scheduled a re-inspection because of this uncertainty. In a similar vein, letting FDA know when you have completed all the corrective actions is crucial, particularly with foreign sites. This lets FDA know that you are ready for a re-inspection.

    Thinking that the Warning Letter citations are all inclusive
    FDA states that the violations listed in a Warning Letter are not all inclusive; however, we frequently hear companies state that, because a certain system wasn’t listed on the Warning Letter or 483 with any observations, it must be acceptable. When it comes to 483s, the investigator may not have focused on a specific area and therefore had no observations. With Warning Letters, the content of the response may have led FDA to accept the response to a specific item, but on re-inspection, the field investigator may find some additional violations. Nothing is off limits.

    When FDA comes to re-inspect
    A lot of times companies think that when FDA comes to re-inspect, they are only going to look at the systems that were cited in the Warning Letter. Many companies fall into this trap thinking that when FDA comes back, they are only going to verify corrective actions. This is just not true. FDA will focus some of the inspection on the corrective actions, but will also, generally, perform a full inspection. The issues identified in the Warning Letter may have been corrected, but new potential issues may be noted. While some of the issues may not warrant additional action, they may lead to a delay in lifting the Warning Letter.

    Some companies aren’t interested in getting the Warning Letter lifted
    Some Warning Letters may not be lifted simply because the company has either abandoned the U.S. market, or has gone out of business.  A small percentage of Warning Letters simply go unanswered, particularly when there isn’t any product on the U.S. market. Other companies, particularly when an Import Alert is in place, may make an initial response, but then discontinue products, move facilities, etc., with the result being no opportunity for the Warning Letter to be lifted. We have no way of knowing how many of the open letters fall into that category.

    Warning Letters are FDA’s practice to allow for firms to take voluntary and prompt corrective actions before initiating a drastic enforcement action such as a seizure or injunction. It goes without saying that firms should demonstrate to FDA their willingness to address the issues raised in the letter in as short of a time frame as is possible, not only to get their Warning Letters lifted as soon as possible, but also to minimize disruption of supply of products to patients. Many companies who have received a Warning Letter have expressed that they desire to have it lifted in a year or less.
    Given the data, this would be an aggressive exception to recent close-out timeframes. While it is theoretically possible to do so in such a short interval, the likelihood of this happening is not high. In addition, because it is critical to demonstrate to FDA that the issues raised in the Waning Letter are being handled, a superficial fix by a firm to reduce time frames could lead to escalated regulatory action by FDA.


    Linda Evans O’Connor
    Lachman Consultants

    Linda Evans O’Connor is head of business processes and regulatory at Lachman Consultants. Ms. Evans O’Connor delivers project oversight/management, work planning and work flow
    analysis, and quality assurance. She can be reached at lcs@lachmanconsultants.com or visit www.lachmanconsultants.com.
    Related Searches
    • fda
    • API
    • Manufacturing
    • it
    Suggested For You
    Mogene Mogene
    Know the Challenges of Biosimilar Manufacturing Know the Challenges of Biosimilar Manufacturing
    Will Immunotherapy Knock Out Cancer? Will Immunotherapy Knock Out Cancer?
    Tapemark Passes Regulatory Hurdle Tapemark Passes Regulatory Hurdle
    BioPharma Services Completes 3 FDA Inspections BioPharma Services Completes 3 FDA Inspections
    Synthetic Genomics Launches cGMP Synthetic Biology Suite  Synthetic Genomics Launches cGMP Synthetic Biology Suite
    Frontida BioPharm Launches Expansion Efforts Frontida BioPharm Launches Expansion Efforts
    The FDA and Metrics The FDA and Metrics
    Advaxis Appoints CBO Advaxis Appoints CBO
    Establishments, Identifications, Submissions and Beyond Establishments, Identifications, Submissions and Beyond
    Generic Drug Trends Generic Drug Trends
    Challenges and Advantages of International Regulatory Inspections Challenges and Advantages of International Regulatory Inspections
    LSNE Completes Two FDA Inspections LSNE Completes Two FDA Inspections
    FDA’s Quality Agreements Guidance FDA’s Quality Agreements Guidance
    Trends Affecting the Generic Drugs Sector in 2017 Trends Affecting the Generic Drugs Sector in 2017

    Related FDA Watch

    • The Importance of Hypothesis Testing During Investigations

      The Importance of Hypothesis Testing During Investigations

      Why it is critical to have controls in place during out-of-specification investigations to provide quality assurance.
      Paul Mason, PhD, Lachman Consultants 11.17.20

    • Biologics, Proteins, Vaccines | Regulatory Affairs
      Ensuring Manufacturing Continuity for Essential Medicines

      Ensuring Manufacturing Continuity for Essential Medicines

      Applying the principles of Quality Risk Management to get medicines to market faster.
      John Darby, M.Sc., Senior Director, Lachman Consultant Services, Inc. 09.09.20

    • Biologics, Proteins, Vaccines
      Pharma’s Fight Against the Coronavirus Pandemic

      Pharma’s Fight Against the Coronavirus Pandemic

      A look at the pharma industry’s concerted effort to develop vaccines against the SARS-CoV-2 virus and therapeutics to treat COVID-19.
      Keith O. Webber, Lachman Consultant Services, Inc. 07.15.20


    • Information Technology | Regulatory Affairs
      Data Integrity: Beyond Electronic Records

      Data Integrity: Beyond Electronic Records

      Get your Data Integrity house in order
      Tim Rhines, Ph.D., Director, Lachman Consultant Services, Inc. 05.05.20

    • Regulatory Affairs
      Inquiring Minds Want to Know, Just Ask FDA

      Inquiring Minds Want to Know, Just Ask FDA

      What you need to know prior to submission
      Michelle Ryder, Lachman Consultant 04.01.20

    • Regulatory Affairs
      The Art of Filing NDA/ANDA Post-Approval Changes to the FDA

      The Art of Filing NDA/ANDA Post-Approval Changes to the FDA

      Some tips to make your trip along the regulatory pathway to report manufacturing changes easier.
      Amy Schutte, Senior Associate, Lachman Consultant Services 03.04.20


    • Regulatory Affairs
      Inactive Ingredients: Where Guidance Needs to Meet Data

      Inactive Ingredients: Where Guidance Needs to Meet Data

      Looking at FDA’s most recent draft guidance and the struggle with inactive ingredients.
      Sharif Ahmed, Lachman Consultants Services 10.15.19

    • Regulatory Affairs
      Continuous Manufacturing and its Regulatory Challenge

      Continuous Manufacturing and its Regulatory Challenge

      ...
      José L. Toro, PhD, Lachman Consultants 09.16.19

    • QA/QC | Validation
      Considerations for Analytical Method Validation Lifecycle Controls

      Considerations for Analytical Method Validation Lifecycle Controls

      ICH is set to implement new regulatory guidance dedicated to analytical method development
      Paul Mason, PhD, Lachman Consultants 07.15.19


    • Regulatory Affairs
      Effective Post Market Supplier Strategy for Combination Products

      Effective Post Market Supplier Strategy for Combination Products

      Combinations are typically designed, developed and maintained under a robust contract manufacturing process
      Lori-Ann Woodard CBA, CQE, CSQE, Lachman Consultant Services 06.13.19

    • QA/QC
      Nitrosamines

      Nitrosamines

      How to address these unwelcome guests in the pharmaceutical world
      Aloka Srinivasan, Ph.D., Lachman Consultant Services 05.07.19

    • Regulatory Affairs
      KASA to Support Generic Drug Review

      KASA to Support Generic Drug Review

      FDA expects the new system to advance OPQ’s focus on pharmaceutical quality, the foundation for ensuring the safety and efficacy of drugs.
      Sharif Ahmed, Lachman Consultant Services 04.05.19


    • Regulatory Affairs
      FDA’s Interpretation of the “Deemed to be a License” Provision of the Biologics Price Competition an

      FDA’s Interpretation of the “Deemed to be a License” Provision of the Biologics Price Competition an

      A look at how the FDA will administer the transition of NDAs to BLAs
      Keith Webber, Ph.D., Lachman Consultant Services 03.06.19

    • Regulatory Affairs
      Reporting CPPs to FDA

      Reporting CPPs to FDA

      Importance of identifying critical process parameters in original submissions to FDA.
      Aloka Srinivasan, Ph.D. Lachman, Consultant Services 10.10.18

    • Regulatory Affairs
      FDA and Field Alert Reports

      FDA and Field Alert Reports

      Analysis of “Field Alert Report Submission Questions and Answers Guidance for Industry”
      Constance Richard-Math, Lachman Consultants 09.11.18

    Trending
    • Catalent Acquires Acorda’s INBRIJA Manufacturing Operations
    • Fujifilm To Invest $2B In US Manufacturing Site
    • Baxter, Novavax Ink Sterile Manufacturing Agreement
    • Precision Medicine Group Acquires Project Farma
    • Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz
    Breaking News
    • KORSCH, MEDELPHARM Partner on R&D Equipment Portfolio
    • Frontage Bolsters Clinical Services Capabilities
    • Sanofi Unveils EUROAPI as Name of New European API Company
    • Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz
    • Precision Medicine Group Acquires Project Farma
    View Breaking News >
    CURRENT ISSUE

    November/December 2020

    • Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up
    • Ensuring Quality During the Transfer and Scale Up of Rx Drugs
    • Inspecting the Unexpected
    • Cold Chain Trends
    • Catering for the Complex
    • Biopharma Contract Manufacturing: Robust Growth Ahead
    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    • The Single-Use Mixing Landscape: Evaluating Your Options
    • Self-Medication: Flexibility for Patients and Drug Manufacturers
    • Decentralized Trials Fuel AI Revolution in Clinical Research
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Brown Fat Associated with Reductions in Chronic Disease Risk
    NIH Study Identifies Antibacterial Properties in Taurine
    NSF Begins New Certification Program
    Coatings World

    Latest Breaking News From Coatings World

    Zeppelin Acquires MTI Mischtechnik
    Ezio Braggio Joins ChemQuest Europe
    IFS Coatings Announce Carbon Offset Program
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Optimize EP Launches CaRM Cardiac Device Data Management Platform
    U.S. TAVR Market Projected to Reach Nearly $5 Billion by 2030
    FDA Clears Canon Medical's Compressed SPEEDER for 3D Exams on 1.5T MR
    Contract Pharma

    Latest Breaking News From Contract Pharma

    KORSCH, MEDELPHARM Partner on R&D Equipment Portfolio
    Frontage Bolsters Clinical Services Capabilities
    Sanofi Unveils EUROAPI as Name of New European API Company
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Neenah to Host Packaging Webinar for Printers
    W.S. Badger is Named a ‘150 Top Impact Company’
    Mana Products, Meiyume and RPG Form The Vertical Beauty Alliance
    Happi

    Latest Breaking News From Happi

    Amyris Named a Top Social & Environmental Impact Company
    L'Oréal Bans Animal Hair in Brushes
    Ashland Launches Antaron ECo Gel
    Ink World

    Latest Breaking News From Ink World

    dar-tech, inc. Becomes U.S. Midwestern Distributor for ZS Interpolymer
    Techkon USA, Konica Minolta Partner
    Alon Bar-Shany Appointed Chairman of Highcon Board
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Exhibitor registration opens for virtual.drupa
    FTA planning in-person Forum & INFOFLEX
    Fortis Solutions Group achieves SGP certification
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Shemesh Adds U.S. Headquarters
    TZMO USA, Special Needs Group Form Partnership
    BAHP Announces 2021 Officers, Board of Directors
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Rapid Recovery Protocol Can Lead to Increased Range of Motion After TKA
    Boston Scientific Releases WaveWriter Alpha Spinal Cord Stimulators in U.S.
    New Chief Clinical Officer on Board at IncludeHealth
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Roadsimple Modernizes Warehouse Ops with Zebra Technologies
    Toppan Announces 2050 Environmental Vision
    SOI Industry Consortium Joins SEMI as Strategic Association Partner

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login